A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN

Abstract Background While pain freedom at 2 h is a key primary outcome for current trials acute treatment of migraine, the relationship between degree head and other efficacy measures has rarely been explored. Following lasmiditan migraine attack with moderate or severe pain, we contrast those who achieve mild but not post dosing. Methods Patient-level data were pooled across studies arms from two Phase 3 comparing placebo, SAMURAI SPARTAN. This hoc analysis assessed most bothersome symptom (MBS), migraine-related functional disability (disability), improved patient global impression change (PGIC) in patients achieved compared to experienced pain. Mild differs relief which defined as either freedom. Results Patients ( N = 913), comparison 864), significantly more likely experience MBS (91.9% vs. 44.9%), (87.1% 13.4%), PGIC (86.5% 31.5%) p < 0.001 all combinations). In addition, free both (83.6%) (10.8%; 0.001). The proportion did (4.6%) was lower than (52.4%). Lastly, 55.2% before 72.1% same time. Conclusions study demonstrated that, treatment, outcomes including their MBS, disability, confirming that robustly associated clinical endpoint. Trial Registration NCT02439320 ); SPARTAN NCT02605174 ).